Sublingual tofacitinib may have a role in the management of alopecia areata with fewer side effects than the oral form of the JAK1/3 inhibitor. An Australian pilot study of sublingual tofacitinib was conducted in 18 patients with moderate to severe, treatment-resistant alopecia. The 18 patients rolled over to sublingual tofacitinib had been non-responders to either ...
Hair & nails
Hair growth achieved with novel formulation of JAK inhibitor
By Mardi Chapman
25 May 2021